A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-4
Publisher
Informa UK Limited
Online
2019-10-16
DOI
10.1080/13543784.2020.1681397
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
- (2019) Alberto Mantovani et al. IMMUNITY
- IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease
- (2019) Jesper Falkesgaard Højen et al. NATURE IMMUNOLOGY
- Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
- (2018) Brendan M. Everett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid
- (2017) Can Cai et al. INFLAMMATION
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
- (2017) Auvro R. Mridha et al. JOURNAL OF HEPATOLOGY
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
- (2017) Philippe Vasseur et al. Oncotarget
- The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
- (2017) Sophie Cazanave et al. Scientific Reports
- Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2016) Herbert Tilg et al. HEPATOLOGY
- Interleukin-18–deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis
- (2016) Kyosuke Yamanishi et al. Translational Research
- Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients
- (2014) Adriana M. Hung et al. JOURNAL OF NEPHROLOGY
- IL-37 protects against obesity-induced inflammation and insulin resistance
- (2014) Dov B. Ballak et al. Nature Communications
- Caspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis
- (2013) Laura J. Dixon et al. PLoS One
- Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice
- (2011) Yehuda Kamari et al. JOURNAL OF HEPATOLOGY
- Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans
- (2011) Jussi Pihlajamäki et al. JOURNAL OF HEPATOLOGY
- Unknown
- (2011) Alexander Moschen et al. MOLECULAR MEDICINE
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
- (2011) Bolormaa Vandanmagsar et al. NATURE MEDICINE
- The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity
- (2010) Rinke Stienstra et al. Cell Metabolism
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now